{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:08:51Z","timestamp":1759936131284,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH NIAD","doi-asserted-by":"publisher","award":["R01AI111532"],"award-info":[{"award-number":["R01AI111532"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.vaccine.2018.05.092","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T22:24:21Z","timestamp":1528323861000},"page":"4346-4353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multi-clade H5N1 virus-like particles: Immunogenicity and protection against H5N1 virus and effects of beta-propiolactone"],"prefix":"10.1016","volume":"36","author":[{"given":"Peter","family":"Pushko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Tretyakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachmat","family":"Hidajat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangjie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Belser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrence M.","family":"Tumpey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.05.092_b0005","first-page":"269","article-title":"Influenza virus-like particles as pandemic vaccines","volume":"333","author":"Kang","year":"2009","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2018.05.092_b0010","doi-asserted-by":"crossref","unstructured":"Creanga A, Hang NLK, Cuong VD, Nguyen HT, Phuong HVM, Thanh LT, et al. Highly pathogenic avian influenza A(H5N1) viruses at the animal-human interface in vietnam, 2003-2010. J Infect Dis 2017;216(suppl_4):S529\u2013S38.","DOI":"10.1093\/infdis\/jix003"},{"key":"10.1016\/j.vaccine.2018.05.092_b0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.virol.2017.08.024","article-title":"Pathogenicity testing of influenza candidate vaccine viruses in the ferret model","volume":"511","author":"Belser","year":"2017","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.05.092_b0020","unstructured":"Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. Releve epidemiologique hebdomadaire\/Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations 2012;16;87(11):97\u2013108."},{"key":"10.1016\/j.vaccine.2018.05.092_b0025","unstructured":"WHO. Antigenic and genetic characteristics of A(H5N1), A(H7N3), A(H9N2) and variant influenza viruses and candidate vaccine viruses developed for potential use in human vaccines; 2013."},{"key":"10.1016\/j.vaccine.2018.05.092_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2013.05.006","article-title":"H5N1 vaccines in humans","author":"Baz","year":"2013","journal-title":"Virus Res."},{"key":"10.1016\/j.vaccine.2018.05.092_b0035","unstructured":"FDA. Vaccines Licensed for Use in the United States. 2017 [cited October 24, 2017]; Available from: <https:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm093833.htm>."},{"issue":"44\u201346","key":"10.1016\/j.vaccine.2018.05.092_b0040","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1016\/j.vaccine.2006.05.101","article-title":"Scientific lessons from the first influenza pandemic of the 20th century","volume":"24","author":"Oxford","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.092_b0045","doi-asserted-by":"crossref","unstructured":"Levine MZ, Holiday C, Liu F, Jefferson S, Gillis E, Bellamy AR, et al. Cross-reactive antibody responses to novel H5Nx influenza viruses following homologous and heterologous prime-boost vaccination with a prepandemic stockpiled A(H5N1) vaccine in humans. J Infect Dis 2017;216(suppl_4):S555\u2013S9.","DOI":"10.1093\/infdis\/jix001"},{"issue":"22 Suppl 5","key":"10.1016\/j.vaccine.2018.05.092_b0050","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.cmi.2015.12.005","article-title":"Universal influenza vaccines: a realistic option?","volume":"01","author":"de Vries","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.092_b0055","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cmi.2017.02.009","article-title":"Universal influenza virus vaccines and therapeutic antibodies","volume":"23","author":"Nachbagauer","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.092_b0060","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3201\/eid1201.051043","article-title":"Making better influenza virus vaccines?","volume":"12","author":"Palese","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.092_b0065","doi-asserted-by":"crossref","unstructured":"Pushko PM, Bright RA, Tumpey TM, Smith GE. Engineering better influenza vaccines: traditional and new approaches. In: Khudyakov YE, editor. Medicinal Protein Engineering. Boca Raton, CRC Press; 2009. p. 169\u2013204.","DOI":"10.1201\/9781420007305.ch8"},{"issue":"7","key":"10.1016\/j.vaccine.2018.05.092_b0070","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1080\/21645515.2017.1313375","article-title":"A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control","volume":"13","author":"Ray","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.05.092_b0075","first-page":"181","article-title":"Live attenuated influenza vaccine","volume":"386","author":"Jin","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2018.05.092_b0080","doi-asserted-by":"crossref","first-page":"e1006682","DOI":"10.1371\/journal.ppat.1006682","article-title":"A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine","volume":"13","author":"Wu","year":"2017","journal-title":"PLoS Pathog"},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.092_b0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000346773","article-title":"Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures","volume":"56","author":"Pushko","year":"2013","journal-title":"Intervirology"},{"issue":"50","key":"10.1016\/j.vaccine.2018.05.092_b0090","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1016\/j.vaccine.2005.07.098","article-title":"Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB\/c mice","volume":"23","author":"Pushko","year":"2005","journal-title":"Vaccine"},{"issue":"35","key":"10.1016\/j.vaccine.2018.05.092_b0095","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1016\/j.vaccine.2011.06.068","article-title":"Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes","volume":"29","author":"Pushko","year":"2011","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.vaccine.2018.05.092_b0100","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1016\/j.vaccine.2016.09.012","article-title":"Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model","volume":"34","author":"Pushko","year":"2016","journal-title":"Vaccine"},{"issue":"501","key":"10.1016\/j.vaccine.2018.05.092_b0105","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.virol.2016.12.001","article-title":"Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens","volume":"15","author":"Pushko","year":"2017","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.05.092_b0110","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.virol.2015.10.007","article-title":"Preparation of quadri-subtype influenza virus-like particles using bovine immunodeficiency virus gag protein","volume":"487","author":"Tretyakova","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.05.092_b0115","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.virol.2017.06.006","article-title":"Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets","volume":"509","author":"Smith","year":"2017","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.05.092_b0120","doi-asserted-by":"crossref","DOI":"10.1021\/acs.bioconjchem.6b00372","article-title":"Bioorthogonal strategy for bioprocessing of specific-site-functionalized enveloped influenza-virus-like particles","author":"Carvalho","year":"2016","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.vaccine.2018.05.092_b0125","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.virol.2017.08.023","article-title":"Live baculovirus acts as a strong B and T cell adjuvant for monomeric and oligomeric protein antigens","volume":"511","author":"Heinimaki","year":"2017","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.092_b0130","doi-asserted-by":"crossref","first-page":"e1501","DOI":"10.1371\/journal.pone.0001501","article-title":"Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle","volume":"3","author":"Bright","year":"2008","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.vaccine.2018.05.092_b0135","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1016\/j.vaccine.2007.01.106","article-title":"Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin","volume":"25","author":"Bright","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.092_b0140","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jviromet.2016.04.013","article-title":"Analysis of the beta-propiolactone sensitivity and optimization of inactivation methods for human influenza H3N2 virus","volume":"235","author":"Sasaki","year":"2016","journal-title":"J Virol Methods"},{"issue":"222","key":"10.1016\/j.vaccine.2018.05.092_b0145","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jviromet.2015.05.004","article-title":"Evaluation of different inactivation methods for high and low pathogenic avian influenza viruses in egg-fluids for antigen preparation","volume":"15","author":"Pawar","year":"2015","journal-title":"J Virol Methods"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.092_b0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.virol.2013.03.027","article-title":"Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses","volume":"442","author":"Tretyakova","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.05.092_b0155","unstructured":"WHO. Recommendations and laboratory procedures for detection of avian influenza A(H5N1) virus in specimens from suspected human cases. 2007 [cited October 24, 2017]; Available from: <http:\/\/www.who.int\/influenza\/resources\/documents\/RecAIlabtestsAug07.pdf>."},{"issue":"11","key":"10.1016\/j.vaccine.2018.05.092_b0160","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1128\/JVI.00207-09","article-title":"Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge","volume":"83","author":"Perrone","year":"2009","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2018.05.092_b0165","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virusres.2004.08.012","article-title":"Assembly and budding of influenza virus","volume":"106","author":"Nayak","year":"2004","journal-title":"Virus Res"},{"issue":"23\u201324","key":"10.1016\/j.vaccine.2018.05.092_b0170","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1002\/pmic.201300096","article-title":"Surface modifications of influenza proteins upon virus inactivation by beta-propiolactone","volume":"13","author":"She","year":"2013","journal-title":"Proteomics"},{"issue":"9857","key":"10.1016\/j.vaccine.2018.05.092_b0175","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/S0140-6736(12)61684-5","article-title":"Prediction and prevention of the next pandemic zoonosis","volume":"380","author":"Morse","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.092_b0180","first-page":"24","article-title":"Cell-based protein vaccines for influenza","volume":"7","author":"Cox","year":"2005","journal-title":"Curr Opin Mol Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2018.05.092_b0185","doi-asserted-by":"crossref","first-page":"e9161","DOI":"10.1371\/journal.pone.0009161","article-title":"H1N1 pandemic influenza virus in mice","volume":"5","author":"Quan","year":"2009","journal-title":"PloS one"},{"issue":"2","key":"10.1016\/j.vaccine.2018.05.092_b0190","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4149\/av_2013_02_91","article-title":"Overview of measles and mumps vaccine: origin, present, and future of vaccine production","volume":"57","author":"Betakova","year":"2013","journal-title":"Acta Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.092_b0195","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/imr.12098","article-title":"Advances in antiviral vaccine development","volume":"255","author":"Graham","year":"2013","journal-title":"Immunol Rev"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.092_b0200","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/2051013615595595","article-title":"Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults","volume":"3","author":"Cox","year":"2015","journal-title":"Ther Adv Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2018.05.092_b0205","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1586\/14760584.2015.1039520","article-title":"Flucelvax (Optaflu) for seasonal influenza","volume":"14","author":"Manini","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.092_b0210","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.09.6","article-title":"Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments","volume":"8","author":"Schotsaert","year":"2009","journal-title":"Expert Rev. Vacc."},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.092_b0215","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nsmb.1574","article-title":"Universal epitopes of influenza virus hemagglutinins?","volume":"16","author":"Wang","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.vaccine.2018.05.092_b0220","unstructured":"Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, et al. Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination. Science (New York, NY July 15)."},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.092_b0225","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/vim.2011.0016","article-title":"Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge","volume":"24","author":"Tang","year":"2011","journal-title":"Viral Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.092_b0230","doi-asserted-by":"crossref","first-page":"e01044","DOI":"10.1128\/mBio.01044-15","article-title":"An intranasal virus-like particle vaccine broadly protects mice from multiple subtypes of influenza A virus","volume":"6","author":"Schwartzman","year":"2015","journal-title":"MBio"},{"issue":"13","key":"10.1016\/j.vaccine.2018.05.092_b0235","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.vaccine.2016.02.011","article-title":"Vaccination with virus-like particles containing H5 antigens from three H5N1 clades protects chickens from H5N1 and H5N8 influenza viruses","volume":"34","author":"Kapczynski","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.092_b0240","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/mt.2012.286","article-title":"Baculovirus: an insect-derived vector for diverse gene transfer applications","volume":"21","author":"Airenne","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2018.05.092_b0245","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-3-319-27216-0_12","article-title":"Fundamentals of baculovirus expression and applications","volume":"896","author":"Kost","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.092_b0250","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/vim.2010.0028","article-title":"Immunogenicity and protective efficacy in mice and hamsters of a beta-propiolactone inactivated whole virus SARS-CoV vaccine","volume":"23","author":"Roberts","year":"2010","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2018.05.092_b0255","unstructured":"WHO. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines. 2012 [cited; Available from: <http:\/\/www.who.int\/influenza\/vaccines\/virus\/characteristics_virus_vaccines\/en\/index.html>."},{"issue":"2","key":"10.1016\/j.vaccine.2018.05.092_b0260","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.virol.2007.08.035","article-title":"Analysis of residues near the fusion peptide in the influenza hemagglutinin structure for roles in triggering membrane fusion","volume":"370","author":"Thoennes","year":"2008","journal-title":"Virology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:26:41Z","timestamp":1759400801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18307588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":52,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0264410X18307588"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.092","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-clade H5N1 virus-like particles: Immunogenicity and protection against H5N1 virus and effects of beta-propiolactone","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}